152 related articles for article (PubMed ID: 6685578)
1. Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia.
Gerad H; Egorin MJ; Whitacre M; Van Echo DA; Aisner J
Cancer Chemother Pharmacol; 1983; 11(3):162-6. PubMed ID: 6685578
[TBL] [Abstract][Full Text] [Related]
2. Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury.
Wondergem J; Bulger RE; Strebel FR; Newman RA; Travis EL; Stephens LC; Bull JM
Cancer Res; 1988 Jan; 48(2):440-6. PubMed ID: 3335012
[TBL] [Abstract][Full Text] [Related]
3. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling.
Baba H; Siddik ZH; Strebel FR; Jenkins GN; Bull JM
Cancer Res; 1989 Dec; 49(24 Pt 1):7041-4. PubMed ID: 2582445
[TBL] [Abstract][Full Text] [Related]
4. Acute systemic toxicity of combined cis-diamminedichloroplatinum and hyperthermia in the rat.
Mella O; Eriksen R; Dahl O; Laerum OD
Eur J Cancer Clin Oncol; 1987 Apr; 23(4):365-73. PubMed ID: 3609102
[TBL] [Abstract][Full Text] [Related]
5. Effect of whole body hyperthermia on cis-diamminedichloroplatinum (II)-induced antitumour activity and tissue Pt-distribution: do anaesthetics influence the therapeutic ratio?
Wondergem J; Siddik ZH; Strebel FR; Bull JM
Eur J Cancer; 1993; 29A(4):549-54. PubMed ID: 8435209
[TBL] [Abstract][Full Text] [Related]
6. A comparison of thermal enhancement of cis-diamminedichloroplatinum (II) induced renal and intestinal toxicities by whole body hyperthermia in the rat.
Wondergem J; Bulger RE; Siddik ZH; Leygraaf JW; Strebel FR; Alonso M; Travis EL; Bull JM
Int J Radiat Oncol Biol Phys; 1989 Jun; 16(6):1551-6. PubMed ID: 2722594
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).
Reece PA; Stafford I; Russell J; Gill PG
Cancer Chemother Pharmacol; 1985; 15(3):295-9. PubMed ID: 4053272
[TBL] [Abstract][Full Text] [Related]
8. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
Ohno S; Strebel FR; Stephens LC; Siddik ZH; Makino M; Klostergaard J; Tomasovic SP; Khokhar AR; Bull JM
Cancer Res; 1992 Aug; 52(15):4096-101. PubMed ID: 1638521
[TBL] [Abstract][Full Text] [Related]
9. Chronic effect of whole-body hyperthermia combined simultaneously with cis-diamminedichloroplatinum (II) on normal tissue in rat.
Wondergem J; Strebel FR; Stephens LC; Siddik ZH; Bull JM
Int J Hyperthermia; 1995; 11(1):37-47. PubMed ID: 7714369
[TBL] [Abstract][Full Text] [Related]
10. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tumor growth in experimental whole body hyperthermia.
Wile AG; Nahabedian MY; Mason GR
J Surg Oncol; 1983 Oct; 24(2):119-23. PubMed ID: 6685213
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.
Dumas M; de Gislain C; d'Athis P; Chadoint-Noudeau V; Escousse A; Guerrin J; Autissier N
Cancer Chemother Pharmacol; 1989; 23(1):37-40. PubMed ID: 2909288
[TBL] [Abstract][Full Text] [Related]
13. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats.
Ohno S; Siddik ZH; Baba H; Stephens LC; Strebel FR; Wondergem J; Khokhar AR; Bull JM
Cancer Res; 1991 Jun; 51(11):2994-3000. PubMed ID: 2032236
[TBL] [Abstract][Full Text] [Related]
14. Effect of altered duration of 41.5 degrees C whole body hyperthermia in combination with cis-diamminedichloroplatinum (II) on tumor and normal tissue apoptosis and tumor response in rats.
Toyota N; Strebel FR; Stephens LC; Rowe W; Matsuda H; Oshiro T; Jenkins GN; Bull JM
Oncol Rep; 1998; 5(5):1231-6. PubMed ID: 9683841
[TBL] [Abstract][Full Text] [Related]
15. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).
Dumas M; de Gislain C; d'Athis P; Chadoint-Noudeau V; Escousse A; Guerrin J; Autissier N
Cancer Chemother Pharmacol; 1990; 26(4):278-82. PubMed ID: 2369792
[TBL] [Abstract][Full Text] [Related]
16. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy.
Goel R; Andrews PA; Pfeifle CE; Abramson IS; Kirmani S; Howell SB
Eur J Cancer; 1990 Jan; 26(1):21-7. PubMed ID: 2156545
[TBL] [Abstract][Full Text] [Related]
18. Absence of whole body hyperthermia effect on cisplatin distribution in spontaneous canine tumors.
Page RL; Lee J; Riviere JE; Dodge RK; Thrall DE; Dewhirst MW
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1097-102. PubMed ID: 7607930
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.
Robins HI; Cohen JD; Schmitt CL; Tutsch KD; Feierabend C; Arzoomanian RZ; Alberti D; d'Oleire F; Longo W; Heiss C
J Clin Oncol; 1993 Sep; 11(9):1787-94. PubMed ID: 8355046
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
